Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 25
---
us also contains
estimates, projections and other information concerning our industry, our business, and our target markets for certain diseases, including
data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or
similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and
circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other
data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical
and general publications, government data, and similar sources.

| 17 |

<div align='center'>USE OF PROCEEDS</div>

Assuming we sell all Units offered pursuant to this prospectus,
we estimate the net proceeds from this offering will be approximately $15.5 million, based on an assumed combined public offering price
of $4.07 per Unit with Depositary Shares (the last reported sale price of our Depositary Shares on the NASDAQ Capital Market on December
4, 2025) and $4.0699 per Unit with Pre-Funded Warrants (the last reported sale price of our Depositary Shares on the NASDAQ Capital Market
on December 9, 2025, minus $0.0001), after deducting placement agent fees and estimated offering expenses payable by us as described in
“Plan of Distribution,” and excluding the proceeds, if any, from the cash exercise of the warrants sold in this offering.

We intend to use the net proceeds
from this offering to fund our development programs, for working capital and other general corporate purposes.

The allocation of the net
proceeds of the offering represents our estimates based upon our current plans and assumptions regarding industry and general economic
conditions, our future revenues and expenditures.

As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon completion of this offering, or the
amount we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds will vary depending
on numerous factors, including the relative success and cost of our research and development programs, our ability to gain access to additional
financing, and other factors described under “Risk Factors” in this prospectus and in our Annual Report on Form 20-F for the
year ended December 31, 2024. As a result, our management will have